
Sign up to save your podcasts
Or


This week on "The Top Line," we explore biopharma layoffs in the first quarter of 2024.
Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. With a notable number of layoff rounds marking the start of the year, they examine the factors behind this ongoing challenge while also highlighting positive industry developments.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
By Fierce Life Sciences4.1
1212 ratings
This week on "The Top Line," we explore biopharma layoffs in the first quarter of 2024.
Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. With a notable number of layoff rounds marking the start of the year, they examine the factors behind this ongoing challenge while also highlighting positive industry developments.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.

3,228 Listeners

1,713 Listeners

4,420 Listeners

2,175 Listeners

386 Listeners

1,993 Listeners

355 Listeners

1,649 Listeners

154 Listeners

96 Listeners

3,992 Listeners

1,448 Listeners

337 Listeners

34 Listeners

170 Listeners